Thin
Metabolic Regulation
High-Quality Dulaglutide CAS NO:923950-08-7 Pricelist, Service
Dulaglutide CAS: 923950-08-7 Reference Standard
HPLC Purity: ≥98.5% | Endotoxin: <5 EU/mg | TFA/Acetate Exchange Validated
Engineered under strict quality control standards, our flagship peptide active pharmaceutical ingredients serve preclinical, clinical, and commercial drug development pipelines across Thailand and ASEAN markets.
Examining the intersection of Thailand's expanding medical tourism infrastructure, government bio-hub incentives, and the rising prevalence of chronic gastrointestinal disorders requiring specialized peptide interventions.
Thailand has evolved from a general leisure destination into one of the world's premier tertiary healthcare hubs. World-class hospital systems in Bangkok, Phuket, and Chiang Mai perform thousands of complex bariatric surgeries, extensive oncological intestinal resections, and intestinal reconstructive procedures each year. Consequently, secondary clinical conditions—such as Short Bowel Syndrome (SBS), chronic mucosal atrophy, and severe intestinal malabsorption—have created an urgent medical demand for long-acting, stable glucagon-like peptide-2 (GLP-2) analogues.
Native GLP-2 is degraded within minutes by the circulating enzyme dipeptidyl peptidase-4 (DPP-4). Clinicians and research institutes in Thailand require robust synthetic alternatives such as Teduglutide, Apraglutide, and engineered dipeptidyl protease-resistant constructs that stimulate intestinal crypt stem cell proliferation, heighten villus height, and significantly decrease reliance on parenteral nutrition (PN).
The Thai Food and Drug Administration (Thai FDA) has rapidly updated its biological and chemical substance import protocols, strictly adopting the ASEAN Common Technical Dossier (ACTD) framework alongside PIC/S GMP quality mandates. Under the strategic banner of the Eastern Economic Corridor (EEC) of Innovation, the Kingdom is actively courting global contract development and manufacturing organizations (CDMOs) to localize advanced bio-manufacturing capabilities.
Procuring GLP-2 analogue APIs requires full traceability, validated Certificate of Analysis (CoA) datasets, and complete CTD Module 3 (Quality/CMC) compliance. Global peptide manufacturers offering direct localized regulatory assistance and validated batch chemistry ensure that domestic Thai formulation laboratories and university research hospitals avoid costly customs holdups and regulatory rejections.
An analytical overview of sequence modification, solid-phase peptide synthesis (SPPS) challenges, counter-ion control, and strategies for eliminating isomeric and truncated impurities.
Glucagon-Like Peptide-2 (GLP-2) is a 33-amino acid proglucagon-derived peptide secreted by enteroendocrine L-cells in the distal ileum and colon. Its primary biological function is intestinotrophic trophic stimulation: it upregulates mucosal blood flow, expands nutrient absorptive surface area, downregulates apoptosis in mucosal epithelial linings, and tightens junctional permeability. However, native human GLP-2 exhibits an in vivo half-life of roughly 7 minutes due to instantaneous enzymatic cleavage by DPP-4 at the Ala2-Asp3 position.
Therapeutic GLP-2 analogues overcome this limitation via precision amino acid substitution. The most widely characterized example, Teduglutide ([Gly2]-GLP-2), replaces alanine with glycine at position 2, preserving receptor binding affinity while creating steric resistance against DPP-4 cleavage. This modification extends systemic exposure substantially, enabling physiological mucosal restoration.
Given the 33-residue sequence length of GLP-2 analogues, our synthesis relies on high-efficiency Fmoc solid-phase peptide synthesis utilizing Wang or 2-Chlorotrityl chloride (CTC) resins. Pseudoproline dipeptides and backbone protecting groups are strategically inserted to disrupt the formation of β-sheet aggregation during elongated chain elongation, ensuring high crude purities.
Long-chain synthetic peptides are prone to sequence deletions, insertion peptides, and D-amino acid enantiomers resulting from excessive coupling cycles. Our production lines use multi-dimensional preparative RP-HPLC with specialized stationary phases (C18 and phenyl-hexyl columns) to separate diastereomeric impurities and resolve truncated sequences with resolution exceeding 99.0%.
Standard peptide synthesis leaves residual Trifluoroacetic acid (TFA), which can cause cytotoxic effects in delicate cell systems and finished injectable formulations. We employ fully validated ion-exchange chromatography systems to convert peptide salts into pharmaceutically acceptable acetate or hydrochloride salts, followed by multi-cycle controlled lyophilization for long-term stability.
| Analytical Parameter | GLP-2 Analogue (Teduglutide Standard) | Testing Methodology | Thai FDA & ASEAN CTD Status |
|---|---|---|---|
| Identity (Molecular Weight) | 3752.1 ± 1.0 Da (Mono-isotopic) | High-Resolution LC-MS / MALDI-TOF | Fully Characterized, Reference Aligned |
| Chemical Purity | ≥99.0% (Single Max Impurity <0.5%) | RP-HPLC (Gradient Phase, 214nm/280nm) | Exceeds ICH Q3A/B Impurity Mandates |
| Chiral Purity (Enantiomers) | D-Amino Acid Content < 0.5% | Chiral GC-MS / Amino Acid Analysis (AAA) | Validated Process Controls |
| Residual Solvents | DMF <880 ppm, MeCN <410 ppm, DCM <600 ppm | Headspace Gas Chromatography (HS-GC) | Complies with ICH Q3C (Class 2 & 3) |
| Bacterial Endotoxin | <0.05 EU/mg (Injectable Grade) | Kinetic Turbidimetric / Chromogenic LAL | Essential for Thai Sterile Finished Formulations |
| Net Peptide Content | ≥85.0% (Residual Counter-Ion & Water Balance) | Elemental Nitrogen Analysis / Quantitative AAA | Accurate Dosing Calculation Data Provided |
Key protocols required to navigate high ambient humidity, custom import clearances, cold chain logistics, and supply continuity across the Asia-Pacific corridor.
Thailand falls under WHO Climatic Zone IVb (Hot and very humid: 30°C / 75% RH). Lyophilized GLP-2 analogues are inherently hygroscopic. Exposure to ambient moisture accelerates deamidation of Asn residues and aggregation. Thinheal utilizes vacuum-sealed, amber borosilicate Type I vials under high-purity nitrogen backfill to maintain thermodynamic stability throughout domestic regional storage.
Direct door-to-door distribution from our Hangzhou manufacturing hub to Bangkok requires uninterrupted temperature monitoring. Consignments are packaged in vacuum-insulated panels (VIP) paired with phase change materials (PCM) maintaining temperatures of -20°C or 2°C–8°C. Real-time GPS and temperature data-loggers eliminate blind spots during staging at Suvarnabhumi Airport customs.
Importing synthetic peptide active ingredients into Thailand mandates precise HS-code classification (Chapter 2937) and pre-approval documentation from the Thai FDA Bureau of Drug Control. We deliver full CMC dossier support, stability data under long-term and accelerated conditions (ICH Q1A), and comprehensive impurity toxicological qualification to expedite customs clearance.
Anticipating the technological shift from mono-therapy intestinal repair to dual GLP-1/GLP-2 co-agonism, non-invasive oral permeation, and sustainable large-scale green peptide manufacturing.
While GLP-1 receptor agonists (e.g., Semaglutide, Dulaglutide) dominate obesity and glycemic markets, the clinical emergence of unimolecular dual incretins represents the next pharmaceutical revolution. Dual GLP-1/GLP-2 co-agonists are uniquely positioned to manage metabolic syndrome while mitigating gastrointestinal adverse events, preserving intestinal barrier integrity, and suppressing systemic endotoxemia caused by gut leakage.
Thinheal’s R&D center actively works with biotechnology pioneers across the Asia-Pacific region, engineering chimeric sequences that exhibit balanced nanomolar potency across both human receptors while maintaining prolonged in vivo half-lives through site-selective acylation (fatty diacid conjugation).
Commercial peptide industrialization historically generated massive organic solvent waste, primarily due to Dimethylformamide (DMF), N-Methyl-2-pyrrolidone (NMP), and hazardous coupling additives. Thinheal has pioneered clean-tech synthesis routes utilizing bio-derived, greener reaction media (such as Cyrene and 2-MeTHF) paired with recycled solvent infrastructure.
With our multi-ton annual capacity, we guarantee reliable multi-kilogram commercial batches for pharmaceutical sponsors in Thailand and beyond. We reconcile stringent cGMP impurity profiles with environmental, social, and corporate governance (ESG) expectations demanded by modern international healthcare groups.
Clear, technically rigorous answers covering synthesis, regulatory clearance, stability storage, and analytical validation for sourcing managers and CMC directors.
Access certified pharmaceutical peptide APIs, customized research reagents, and regenerative active sequences tailored for clinical institutions and research laboratories in Thailand.
Whether you require analytical reference standards, validation batches for Thai FDA regulatory registration, or multi-kilogram commercial supply, our technical team is ready to assist your project.
Send Inquiry Now